PAO Group, Inc.

Recent News

  • PAOG Announces Opportunity To Expand CBD Pharmaceutical Research

    Sandusky, Ohio--(Newsfile Corp. - April 13, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company's ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."Since the acquisition, PAOG engaged...

    2021-04-13 10:28 AM EDT
  • PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

    Sandusky, Ohio--(Newsfile Corp. - April 12, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the Company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR...

    2021-04-12 11:00 AM EDT
  • PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

    Sandusky, Ohio--(Newsfile Corp. - April 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company's ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021.Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING...

    2021-04-08 11:39 AM EDT
  • PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ

    Sandusky, Ohio--(Newsfile Corp. - March 16, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released details on the Company's nutraceutical developments initiative following last week's introduction of adding CBD RELAX-RX to existing CBD RespRx developments. The details today are highlighted by the Company's September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis Holdings, Inc. (OTC Pink: USMJ).PAOG is...

    2021-03-16 9:09 AM EDT
  • PAOG Announces Save The Date For CBD Nutraceuticals Expansion Update

    Sandusky, Ohio--(Newsfile Corp. - March 10, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today encouraged all interested to save the date, Tuesday, March 16, 2021, when PAOG will publish details on the company's CBD RELAX-RX nutraceutical development plans including intended co-packing with Alkame Holdings, Inc. (OTC Pink: ALKM) and marketing with North American Cannabis Holdings, Inc. (OTC Pink: USMJ).CBD RELAX-RX targets the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.The company recently...

    2021-03-10 1:07 PM EST
  • PAOG CBD RELAX-RX Co-Packing with ALKM And Marketing with USMJ Detailed In Update Scheduled Next Week

    Sandusky, Ohio--(Newsfile Corp. - March 9, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update scheduled one week from today, for Tuesday, March 16, 2021 to publish details on the company's CBD RELAX-RX nutraceutical development plans including intended co-packing with Alkame Holdings, Inc. (OTC Pink: ALKM) and marketing with North American Cannabis Holdings, Inc. (OTC Pink: USMJ).CBD RELAX-RX targets the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.The company...

    2021-03-09 12:58 PM EST
  • PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

    Sandusky, Ohio--(Newsfile Corp. - March 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). Last year, PAOG acquired RespRx from Kali-Extracts, Inc....

    2021-03-08 11:04 AM EST
  • PAOG Expects To Realize Revenue This Year From New CBD Nutraceuticals

    Sandusky, Ohio--(Newsfile Corp. - February 18, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today highlighted the company's anticipated revenue expected this year from its CBD nutraceutical expansion. Earlier this week, the company published an online, multimedia presentation detailing the company's CBD nutraceutical development expansion plans. The presentation includes details on PAOG's strategic engagements with Puration, Inc. (OTC Pink: PURA), North American Cannabis Holdings, Inc. (OTC Pink: USMJ) and Alkmae Holdings, Inc. (OTC Pink: ALKM).Follow the links below...

    2021-02-18 9:43 AM EST